Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540203 | 0.89 | BCHE (0.39) | HTR2CHTR2ABCHEACHERAB9A | |
| SCHEMBL3543021 | 0.88 | BCHE (0.40) | BCHEACHERAB9AMEN1MAPK1 | |
| SCHEMBL3545018 | 0.88 | KCNQ2 (0.40) | HTR2CHTR2ACNR1CNR2LMNA | |
| SCHEMBL3546473 | 0.88 | RORC (0.41) | HTR2CHTR2ARAB9AMEN1KMT2A | |
| SCHEMBL3539382 | 0.87 | BCHE (0.40) | HTR2CHTR2ABCHEACHERAB9A | |
| SCHEMBL3546454 | 0.87 | KCNQ2 (0.41) | HTR2CHTR2ACNR1CNR2 | |
| SCHEMBL3545321 | 0.86 | HTR2C (0.43) | HTR2CHTR2ABCHEACHEMEN1 | |
| SCHEMBL3551076 | 0.84 | CNR2 (0.41) | HTR2CHTR2AMEN1MAPK1KMT2A | |
| SCHEMBL3540288 | 0.84 | RAB9A (0.39) | HTR2CHTR2AHTTBCHEACHE | |
| SCHEMBL3541848 | 0.83 | MAPT (0.40) | HTR2CHTR2ABCHEACHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | claimed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | claimed |
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662831-B2 | Tetracyclic indoles as potassium channel modulators | WYETH LLC (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027090-A1 | TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA5, KCNK5 | HTR2C 223/4885HTR2A 267/4885HTT 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.